Questions about Lequmbi

I'd say a definitive maybe, it depends on how early you started on Leqembi in your progression of AD. In the Phase 3 trial for Leqembi, Eisai (drug company primary responsible for Leqembi) has presented results showing that after 18 months of treatment, 76% of the people in the no/low tau subgroup maintained their same cognitive score. This is compared to 55% of those on placebo in the no/low tau group who maintained their same score. Tau is another biological abnormality in the brains of people with AD, separate and distinct from amyloid plaque. Monoclonal anti-body drugs like Leqembi & Kisunla target amyloid plaque, but they unfortunatelty do not perform so well at reducing tau. That is why combination therapy, pairing an anti-amyloid drug with an anti-tau drug may be the wave of the future for AD treatments.

As noted by Laura2020, after 18 months of bi-weekly infusions of Leqembi, the standard recommendation is to continue with monthly maintenance infusions. Laura2020 also notes that at the end of this month, Eisai is awaiting FDA approval of a subcutaneous version of Leqembi for maintenance dosing. This fancy term means no more infusions. Instead, you would receive a weekly shot of Leqembi.

Will all of this keep you out of an ALF (I had to look up the term in the commonly used abbreviations log :) )? Possibly. Again, one key factor may be how early you started on Leqembi. If you started later in the disease process, then Leqembi might slow down the disease process, but not keep you out of ALF. But if you started early, then there may be a chance that Leqembi could keep you out of ALF. Specifically, you might retain enough cognition until an anti-tau drug gets approved by the FDA, at which time you could then wipe out both the amyloid and the tau in your brain, thus giving you much better odds for staying out of ALF.

This is at least my assessment of the situation, as a non-medical expert.